Pharmacogenomic (PGx) testing is a growing area of personalized medicine with demonstrated clinical utility in improving patient outcomes in oncology. PGx testing of pharmacogenes affecting drug ...
If a pharmacogenomic test result can significantly impact on a treatment decision, either to contraindicate usage of a drug or biologic agent or adjust dosing, product labeling should be modified ...
The genetic testing market accounted for $ 12,682 million in 2019, and is expected to reach $ 21,260 million by 2027, registering a CAGR of 10.1% from 2020 to 2027. The global genetic testing market ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealthcare (UNH) following the Nov 1, 2024 publication ...
They also suggest that a pharmacogenomic test may one day be available that can give physicians the opportunity to not only be aware of a particular patient's risk, but be able to weigh the ...